Written Question·Department of Health and Social Care·UIN 45872
Glioblastoma: Immunotherapy
Tabled: 17 April 2025
Answered: 29 April 2025
Question
Sarah Owen
Labour — Luton North
To ask the Secretary of State for Health and Social Care, when he expects the Medicines and Healthcare products Regulatory Agency will make public their decision on licensing the personalised immunotherapy developed to treat the malignant brain tumour gli
Answer
Karin SmythNorthwest Biotherapeutics has submitted a Marketing Authorization Application to the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) for DCVax-L, an immunotherapy for glioblastoma. The MHRA is working with the applicant to reac...
ⓘ
This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 45872) →
Partner sites